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Abstract
Background: Hypertension is a risk factor for coronary heart disease and stroke, and is one of the leading causes
of death. Although over a billion people are affected worldwide, only half of them receive adequate treatment.
Current guidelines on antihypertensive treatment recommend combination therapy for patients not responding
to monotherapy, but as the number of pills increase, patient compliance tends to decrease. As a result, fixed-dose
combination drugs with different antihypertensive agents have been developed and widely used in recent years.
CCBs have been shown to be better at reducing central blood pressure and arterial stiffness than diuretics. Recent
studies have reported that central blood pressure and arterial stiffness are associated with cardiovascular outcomes.
This trial aims to compare the efficacy of combination of calcium channel blocker (CCB) or thiazide diuretic with an
angiotensin receptor blocker (ARB).
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Methods: This is a multicenter, double-blinded, active-controlled, phase 4, randomized trial, comparing the
antihypertensive effects of losartan/amlodipine and losartan/hydrochlorothiazide in patients unresponsive to
treatment with losartan. The primary endpoint is changes in mean sitting systolic blood pressure (msSBP)
after 4 weeks of treatment. Secondary endpoints are changes in msSBP, mean 24-h ambulatory mobile blood
pressure, mean 24-h ambulatory mobile central SBP, mean 24-h ambulatory carotid-femoral pulse wave velocity,
ambulatory augmentation index, and microalbuminuria/proteinuria after 20 weeks of treatment. The sample size
will be 119 patients for each group in order to confer enough power to test for non-inferiority regarding the
primary outcome.
Conclusion: The investigators aim to prove that combination of a CCB with ARB shows non-inferiority in lowering
blood pressure compared with a combination of thiazide diuretic and ARB. We also hope to distinguish the subset of
patients that are more responsive to certain types of combination drugs. The results of this study should aid physicians
in selecting appropriate combination regimens to treat hypertension in certain populations.
Trial registration: ClinicalTrials.gov NCT02294539. Registered 12 November 2014.
Keywords: Hypertension, Angiotensin II receptor blocker, Calcium channel blocker, Central blood pressure,
Arterial stiffness, Fixed dose combination
Background
Hypertension is known to be a major contributor to cor-
onary heart disease and stroke, which ranks second and
third in causes for death in Korea [1]. According to data
from the Korea National Health and Nutrition Examin-
ation Survey (KNHANES), more than 50% of the Korean
population over age 60 is prevalent with hypertension.
For each 20/10 mmHg increase in systolic/diastolic
blood pressure, the risk of coronary heart disease in-
creases twofold. Treating high blood pressure prevents
clinical events and saves lives [2, 3]. However, lowering
blood pressure is not an easy task, and typically requires
more than one drug to do the job.
Current guidelines on treating hypertension state that
initial therapy should include a thiazide-type diuretic,
calcium channel blocker (CCB), angiotensin-converting
enzyme (ACE) inhibitor, or angiotensin receptor blocker
(ARB) [4]. If the blood pressure goal is not met, doses
should be increased or other classes should be added on
to achieve the target blood pressure. More than 2/3 of
patients with hypertension fail to achieve the goal with
monotherapy, requiring multiple drugs with different
mechanisms to achieve target blood pressure [5]. Com-
bination therapy has been shown to enhance efficacy
while reducing adverse events [6]. However, by increas-
ing the number of drugs one has to take, there remains
a risk of decreased compliance.
Fixed-dose combination (FDC) therapy for hyperten-
sion started in the 1960s with combination of hydro-
chlorothiazide (HCT) and triamterene, and since then
different combinations using diuretics, CCBs, and renin-
angiotensin system (RAS) inhibitors have been
introduced [7, 8]. The rationale of FDC therapy is that
lower doses of each drug can be used to reduce side
effects while maintaining or even potentiating antihyper-
tensive effects. In a study regarding Korean hypertensive
patients, single pill therapy showed a significant increase
in compliance and persistence, [9] which in turn leads to
a decrease in cardiovascular morbidity and mortality.
RAS inhibitors combined with diuretics or CCBs are
one of the recommended regimens for patients unre-
sponsive to monotherapy. Combinations with either
diuretics or CCBs provide synergistic blood pressure
lowering effects and lower the probability of side ef-
fects. However, according to the ACCOMPLISH trial
comparing the combination of ACE inhibitor with
either CCB or HCT, the ACE inhibitor/CCB combo
showed better cardiovascular outcomes in high-risk pa-
tients [10]. More recent trials on Japanese patients have
also shown that ARB/CCB combination have similar
effects on blood pressure and diastolic function com-
pared with ARB/thiazide diuretic combinations [11, 12].
This study was designed to compare the antihyperten-
sive effects of fixed-dose combination therapy of losar-
tan/amlodipine (LST/AML) with that of losartan/
hydrochlorothiazide (LST/HCT) in patients with hyper-
tension unresponsive to monotherapy with losartan. In
addition, this is the first study to compare the cardiovas-
cular protective effects of two combinations, by monitor-
ing 24-h blood pressure and pulse wave velocity, which
have correlations with cardiovascular outcome.
Methods/design
Study objectives
The hypothesis of this trial is that fixed dose combination
of losartan and amlodipine will be non-inferior to combin-
ation of losartan and hydrochlorothiazide in reducing
blood pressure in patients with hypertension. Patient
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blood pressure was measured by conventional and
ambulatory monitoring methods, and other vascular
hemodynamic parameters were also obtained to test the
hypothesis.
Primary endpoint
The primary endpoint is the change in mean sitting sys-
tolic blood pressure (msSBP) after 4 weeks of treatment.
Secondary endpoints
Secondary endpoints are changes in msSBP, mean 24-h
ambulatory mobile blood pressure (AMBP), mean 24-h
ambulatory mobile central SBP (AMcSBP), mean 24-h
ambulatory carotid-femoral pulse wave velocity
(AMPWV), ambulatory augmentation index (AMAIx),
and microalbuminuria/proteinuria after 20 weeks of
treatment. Treatment compliance, response rate, and
success rate are also included in the secondary efficacy
evaluation. Response to treatment is defined as a de-
crease in systolic blood pressure exceeding 20 mmHg or
10 mmHg for diastolic blood pressure, in accordance
with the Korea Food and Drug Administration (KFDA).
Treatment success is defined as blood pressure reaching
a target of <140/90 mmHg.
Blood pressure measurements
Blood pressure measurements will be obtained in the sit-
ting position with the pressure cuff placed at either the
right or left brachial area, using a semi-automated
sphygmomanometer (HEM-7080IC, Omron Healthcare
Co, Kyoto, Japan). After 5 min of rest, blood pressure
will be measured 3 times with an interval of 2 min, and
mean pressure will be used for analysis.
Ambulatory monitoring and aortic stiffness measurement
Ambulatory measurements of peripheral and central
blood pressure, carotid-femoral pulse wave velocity
(cfPWV), and augmentation index (AIx) will be
performed using a previously validated, automated
oscillometric device (Mobil-O-graph 24 h PWA monitor,
IEM Gmbh, Stolberg, Germany) [13–16].
Study design
The trial has a multicenter, double-blinded, active-
controlled, randomized design to compare the efficacy of
fixed dose combination of losartan and amlodipine with
that of losartan and hydrochlorothiazide. The detailed
study design is shown in Fig. 1. Written consent will be
obtained for all study patients, and patients will be per-
mitted to request withdrawal from treatment at any time
without providing reasons. The primary investigators
and the attending physician will also have authority to
drop out patients from the trial if it is considered that
further participation would be detrimental to the
patients’ well-being. After screening, patients eligible for
the trial go through an open-labeled run-in period.
Patients previously diagnosed with hypertension or those
newly diagnosed are given losartan 50 mg daily for
4 weeks. The objective of the run-in period is to uncover
patients not responding to a single class of antihyperten-
sive treatment.
After 4 weeks of run-in, only patients with msSBP
≥140 mmHg will go through randomization and be
given blinded treatment assignments. For the next
4 weeks, eligible patients are given either losartan/
amlodipine 50/5 mg daily or losartan/hydrochlorothia-
zide 50/12.5 mg daily with a placebo drug of the other
group. For patients not responding (msSBP
≥140 mmHg) to the first 4-week arm of the trial, doses
will be increased to losartan/amlodipine 100/5 mg daily
or losartan/hydrochlorothiazide 100/25 mg daily. The
second arm of the trial will last for 16 more weeks.
Patients responding to the initial dose will be main-
tained on their regimen.
Randomization is achieved by block randomization
method to avoid bias and increase inter-group
Fig. 1 Study design
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comparability. Block size is determined by an independ-
ent individual not participating in the trial. Patients are
randomized 1:1 to either losartan/amlodipine or losar-
tan/hydrochlorothiazide. Randomization results are kept
in a sealed envelope and opened only in case of serious
adverse events. Both the investigators and study partici-
pants are blinded to treatment group. To avoid treat-
ments being visually distinguishable, the study drug and
placebo are identical in appearance.
Patient population
Inclusion criteria
Patients are to be recruited from 20 nationwide medical
centers in Korea. Men and women from ages 19 to 80,
with history of hypertension or those newly diagnosed with
a systolic BP ≥140 mmHg are to be included in the study.
Exclusion criteria
The exclusion criteria are: (1) mean sitting diastolic blood
pressure (msDBP) ≥110mgHg or msSBP ≥180 mmHg at
screening or randomization; (2) variability of ≥20 mmHg
in SBP or ≥10 mmHg in DBP between three measure-
ments, or differences of ≥20/10 mmHg in left-to-right bra-
chial values of SBP or DBP; (3) secondary hypertension;
(4) malignant hypertension; (5) allergies or contraindica-
tions to ARB, CCB, or sulfonamides; (6) uncontrolled
diabetes mellitus (HbA1c ≥10%); (7) history of New York
Heart Association (NYHA) class III to IV heart failure, an-
gina, myocardial infarction, cardiomyopathy, arrhythmia,
or aortic stenosis requiring treatment within 6 months; (8)
cerebral vascular disease within 6 months; (9) serious liver
or renal dysfunction; (10) symptomatic hyperuricemia or
gout; (11) galactose or lactose-intolerance; (12) patients
with diabetes or moderate to severe renal dysfunction on
drugs containing aliskiren; (13) pregnancy or the possibil-
ity of pregnancy, or breast feeding; (14) unable to withhold
current medication; (15) prescription of other study
drugs within 4 weeks; and (18) abnormal laboratory
results (AST, ALT >3ULN, Cr >2.0 mg/dL, K+ <3.5 or
>5.5 mEq/L, Na + <125 mEq/L, Protein >2+ on dip-
stick, or protein/creatinine >1000 mg/g on spot urine).
Statistical analysis
Sample size
Sample size is calculated with 90% power to detect a dif-
ference in change of SBP of 3 mmHg between two
groups at a two-sided significance level of 5%. To satisfy
these assumptions and allowing for a drop-out rate of
20%, a total of 238 patients (119 for each treatment arm)
are required for the trial.
Efficacy evaluation
Baseline characteristics will be compared using the Stu-
dents t-test for continuous variables and the chi-square
or Fisher’s exact test for categorical variables. Primary
endpoint evaluation will be carried out using the two-
sample t-test or Mann-Whitney test for inter-group
comparison. For secondary endpoints, two-sample t-test
and Wilcoxon’s rank sum test will be used for continu-
ous variables, and the chi-square or Fisher’s exact test
for categorical variables. Comparison of groups in
achieving blood pressure target will be carried out using
chi-square or McNemar’s test. All efficacy evaluations
will be performed on the full analysis set (FAS). The FAS
is a modified intention-to-treat set that includes patients
receiving at least one dose of the study drug and having
undergone at least one efficacy evaluation. Additional
analysis will also be performed on the per protocol set.
In order to minimize missing data, outcome data for
patients who were discontinued from the study due to
various reasons will be obtained and used for analysis.
All investigators, sponsors, and regulators will aim to
maximize the number of participants who are
maintained on the assigned treatment until outcome
data are collected.
Safety analysis
Safety analysis will be performed on all patients who has
received the study drug at least once. Patients with self-
reported or observed adverse symptoms will be seen by
the attending physician and recorded according to treat-
ment group and severity, and encoded to a system-organ
class according to the Medical Dictionary for Regulatory
Activities (MedDRA), version 16.0. The association with
symptoms and drug treatment will also be evaluated.
Abnormalities in laboratory results will be followed up




This study aims to compare the efficacy of two different
types of losartan based combination drugs on blood
pressure and vascular hemodynamic parameters. While
previous studies have compared LOS/AML with LOS/
HCT and have shown non-inferior antihypertensive re-
sults, [17] this trial will also investigate the effect two
drugs have on central blood pressure and arterial stiff-
ness. Central blood pressure and arterial stiffness are in-
dependent predictors of cardiovascular outcome, [18]
and this is the first trial to study these parameters in
losartan-based combination drugs.
The combination of ARB and CCB has proved to be
beneficial beyond its additive BP reduction capabilities.
ARBs selectively inhibit angiotensin II, which are potent
vasoconstrictors. ARBs decrease blood pressure by vaso-
dilation, and also decrease secretion of aldosterone,
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which in turn has protective effects in diabetic patients.
CCBs relax smooth muscles and afferent arterioles in
the kidney, leading to increased filtration in the glom-
erulus and finally resulting in reduced blood pressure.
However, a well-known side effect of CCBs are periph-
eral edema and vasoconstriction. ARBs can reduce these
side effects by antisympathetic effects and venous dila-
tion. In addition, ARBs can lower the effect of increased
renin-angiotensin-aldosterone (RAA) system, which rises
from using CCBs [19]. It has also been reported that use
of an ARB is associated with lower incidence of diabetes,
while use of a diuretic is associated with a higher inci-
dence [20]. The combination RAS inhibitor with a CCB
is superior to a diuretic combination in avoiding the
stimulation of the RAA system, reducing oxidative
stress, reducing arterial stiffness, and slowing vascular
aging [21]. In the ACCOMPLISH trial, combination with
ACE inhibitor/CCB showed better outcomes compared
to combination with ACE inhibitor/HCT [10]. ARBs
may be preferred over ACE inhibitors as they have com-
parable antihypertensive effects and are associated with
better tolerability.
The difference of this study compared to other non-
inferiority trials is that we aim to measure noninvasive
hemodynamic parameters in addition to conventional
blood pressure. Conventional, clinic measured brachial
blood pressure has its limitations. Clinic blood pressure
does not reflect the daily peak-trough variations and can
be masked by whitecoat hypertension. Furthermore, re-
cent studies have shown that central blood pressure
might be a better predictor of cardiovascular outcomes.
According to the CAFE study, even with comparable
reductions in brachial blood pressure, clinical outcome
tends to differ due to the difference in reduction of cen-
tral blood pressure [22]. While ACE inhibitors, ARBs,
CCBs, and diuretics show comparable efficacy in lower-
ing brachial blood pressure, diuretics are less effective
than others in lowering central blood pressure because it
lacks vasodilation abilities [23–25].
Arterial stiffness is also an useful tool to predict car-
diovascular outcome and to evaluate subclinical organ
damage in hypertensive patients [26]. Assessment of
arterial stiffness can be accomplished by measuring the
PWV or augmentation index from noninvasive monitor-
ing of pulse waveforms [27]. Increased arterial stiffness
results in increased systolic blood pressure and is inde-
pendently associated with an increased risk of cardiovas-
cular disease [28].
The investigators hypothesize that the blood pressure
lowering effects of LOS/AML combination will be
comparable to that of LOS/HCT while having fewer side
effects. Additionally, through measuring central blood
pressure, augmentation index, and PWV, this trial will
test the hypothesis that while showing comparable blood
pressure lowering effects, an ARB/CCB combination
(losartan/amlodipine) has greater cardiovascular benefits
than an ARB/diuretic combination (LOS/HCT).
Conclusion
Current hypertension treatment guidelines strongly ad-
vocate the need to use combination therapy for patients
not responsive to monotherapy. However, there is no
clear directive on which combination would be most ef-
fective and also have beneficial cardiovascular outcomes.
The importance of this study is that it will compare cen-
tral blood pressure and vascular hemodynamic parame-
ters that have correlation with clinical outcomes. The
results of this trial should aid physicians in selecting the
appropriate combination drug to treat hypertension in
certain populations.
Acknowledgements
The contributions of the Korean Society of Hypertension and Hanmi
Pharmaceuticals are gratefully acknowledged.
Funding
This study was supported by a research grant from Hanmi Pharmaceutical
Co., Ltd. (HM-IIT-AMST-003).
Availability of data and materials
Not applicable.
Authors’ contributions
OGC wrote the manuscript. CWJ, YHJ, CEJ, SKC, CSC, YBS, PCG, HSJ, KYK, HTJ,
CDJ, HMS, HJW, KYJ, AY, CMC, KSG, SJ, PS, and SIS participated in the design
of the study. KCJ and LHY designed the study, wrote the manuscript, and
gave final approval of the version to be published. All authors read and
approved the final manuscript.
Ethics approval and consent to participate
This trial will be performed in accordance with the declaration of Helsinki. All
investigators will be required to obtain approval from the institutional review
boards (IRB) from each participating center. All patients will sign a written
consent form approved by the IRB. The study is also in accordance to the Korean
good clinical practice (KGCP) and the international conference on harmonization-
good clinical practice (ICH-GCP). (Clinicaltrials.gov Identifier: NCT02294539).
Consent for publication
Although the manuscript does not involve any clinical data, consent will be
obtained for the data to be published at the time of recruitment into the study.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Division of Cardiology, Department of Internal Medicine, Seoul National
University Hospital, Seoul, Korea. 2Division of Cardiovascular Disease,
Department of Internal Medicine, Gachon University Gil Hospital, Medical
Center, Incheon, Korea. 3Department of Cardiology, Cardiovascular Center,
Seoul St. Mary’s Hospital, Seoul, Korea. 4Division of Cardiology, St. Paul’s
Hospital, Seoul, Korea. 5Division of Cardiology, Department of Medicine,
Kangbuk Samsung Hospital, Seoul, Korea. 6Division of Cardiology,
Department of Internal Medicine, Kyungpook National University Hospital,
Daegu, Korea. 7Division of Cardiology, Department of Internal Medicine,
Yonsei University Wonju Hospital, Wonju, Korea. 8Department of Cardiology,
Korea University Guro Hospital, Seoul, Korea. 9Department of Cardiology,
Oh et al. Clinical Hypertension  (2017) 23:18 Page 5 of 6
Cardiovascular Center, Korea University Anam Hospital, Seoul, Korea.
10Division of Cardiology, Department of Internal Medicine, Dongguk
University Ilsan Hospital, Goyang, Korea. 11Division of Cardiology, Department
of Internal Medicine, Pusan National University Hospital, Busan, Korea.
12Cardiovascular Center, Division of Cardiology, Seoul National University
Bundang Hospital, Seongnam, Korea. 13Division of Cardiology, Department of
Internal Medicine, Soonchunhyang Seoul Hospital, Seoul, Korea. 14Division of
Cardiology, Department of Internal Medicine, Severance Cardiovascular
Hospital, Seoul, Korea. 15Division of Cardiology, Department of Internal
Medicine, Yeungnam University Hospital, Busan, Korea. 16Division of
Cardiology, Department of Internal Medicine, Chonnam National University
Hospital, Gwangju, Korea. 17Division of Cardiology, Department of Internal
Medicine, Chungbuk National University Hospital, Cheongju, Korea. 18Division
of Cardiology, Department of Internal Medicine, Hanyang University Guri
Hospital, Guri, Korea. 19Division of Cardiology, Department of Internal
Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea.
20Cardiovascular Center, Kyung Hee University Hospital at Gangdong, 892
Dongnam-ro, Gangdong-gu, Seoul, Korea.
Received: 23 April 2017 Accepted: 18 August 2017
References
1. Korea, S. Annual report on the causes of death statistics [internet]. Statistics
Korea: Daejeon; 2015.
2. Five-year findings of the hypertension detection and follow-up program. I.
Reduction in mortality of persons with high blood pressure, including mild
hypertension. Hypertension detection and follow-up program cooperative
group. JAMA. 1979;242(23):2562–71.
3. Prevention of stroke by antihypertensive drug treatment in older persons
with isolated systolic hypertension. Final results of the systolic hypertension
in the elderly program (SHEP). SHEP cooperative research group. JAMA.
1991;265(24):3255–64.
4. James PA, et al. 2014 evidence-based guideline for the management of
high blood pressure in adults: report from the panel members appointed to
the eighth joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.
5. Shin J, et al. 2013 Korean Society of Hypertension guidelines for the
management of hypertension. Part II-treatments of hypertension. Clin
Hypertens. 2015;21:2.
6. Wald DS, et al. Combination therapy versus monotherapy in reducing blood
pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med.
2009;122(3):290–300.
7. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of
fixed-dose combination therapy. Arch Intern Med. 1996;156(17):1969–78.
8. Weir MR, Bakris GL. Combination therapy with Renin-Angiotensin-
aldosterone receptor blockers for hypertension: how far have we come? J
Clin Hypertens (Greenwich). 2008;10(2):146–52.
9. Min JY, et al. Compliance and persistence of free-combination
antihypertensive therapy versus single-pill combination in Korean
hypertensive patients. Int J Cardiol. 2013;168(4):4576–7.
10. Jamerson K, et al. Benazepril plus amlodipine or hydrochlorothiazide for
hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28.
11. Kondo K, et al. Comparison of telmisartan/amlodipine and telmisartan/
hydrochlorothiazide in the treatment of Japanese patients with uncontrolled
hypertension: the TAT-Kobe study. Blood Press Monit. 2016;21(3):171–7.
12. Toh N, et al. Effect of diuretic or Calcium-Channel blocker plus Angiotensin-
receptor blocker on diastolic function in hypertensive patients. Circ J. 2016;
80(2):426–34.
13. Wei W, et al. Validation of the mobil-O-graph: 24 h-blood pressure
measurement device. Blood Press Monit. 2010;15(4):225–8.
14. Weber T, et al. Validation of a brachial cuff-based method for estimating
central systolic blood pressure. Hypertension. 2011;58(5):825–32.
15. Hametner B, et al. Oscillometric estimation of aortic pulse wave velocity:
comparison with intra-aortic catheter measurements. Blood Press Monit.
2013;18(3):173–6.
16. Papaioannou TG, et al. Non-invasive 24 hour ambulatory monitoring of
aortic wave reflection and arterial stiffness by a novel oscillometric device:
the first feasibility and reproducibility study. Int J Cardiol. 2013;169(1):57–61.
17. Suh SY, et al. Efficacy and tolerability of amlodipine camsylate/losartan 5/
100-mg versus losartan/hydrochlorothiazide 100/12.5-mg fixed-dose
combination in hypertensive patients nonresponsive to losartan 100-mg
monotherapy. Clin Ther. 2014;36(10):1402–11.
18. Laurent S, Boutouyrie P. Recent advances in arterial stiffness and wave
reflection in human hypertension. Hypertension. 2007;49(6):1202–6.
19. Suarez C. Single-pill telmisartan and amlodipine: a rational combination for
the treatment of hypertension. Drugs. 2011;71(17):2295–305.
20. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive
drugs: a network meta-analysis. Lancet. 2007;369(9557):201–7.
21. Ishimitsu T. Antihypertensive therapy considering the prevention of vascular
aging. J Korean Soc Hypertens. 2011;17(3):85–94.
22. Williams B, et al. Differential impact of blood pressure-lowering drugs on
central aortic pressure and clinical outcomes: principal results of the conduit
artery function evaluation (CAFE) study. Circulation. 2006;113(9):1213–25.
23. Dahlof B, et al. Prevention of cardiovascular events with an antihypertensive
regimen of amlodipine adding perindopril as required versus atenolol
adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac
outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre
randomised controlled trial. Lancet. 2005;366(9489):895–906.
24. Boutouyrie P, et al. Amlodipine-valsartan combination decreases central
systolic blood pressure more effectively than the amlodipine-atenolol
combination: the EXPLOR study. Hypertension. 2010;55(6):1314–22.
25. Jiang XJ, et al. Superior effect of an angiotensin-converting enzyme
inhibitor over a diuretic for reducing aortic systolic pressure. J Hypertens.
2007;25(5):1095–9.
26. Taylor J. 2013 ESH/ESC guidelines for the management of arterial
hypertension. Eur Heart J. 2013;34(28):2108–9.
27. Rhee M-Y, Lee H-Y, Park JB. Measurements of arterial stiffness:
methodological aspects. Korean Circ J. 2008;38(7):343–50.
28. Lee S-J, Park S-H. Arterial Ageing. Korean Circ J. 2013;43(2):73–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Oh et al. Clinical Hypertension  (2017) 23:18 Page 6 of 6
